The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutic Pipeline Program, 2015Inhibitors of Alpha-synuclein Oligomers for the Treatment of Parkinson’s Disease
Study Rationale:
The alpha-synuclein protein forms oligomers (protein clumps) that cause toxicity in the brains of individuals with Parkinson’s disease (PD). We have developed methods that can measure... -
Therapeutics Development Initiative, 2006Evaluation of the Neuroprotective Peptide NAPVSIPQ in Models of Parkinson's Disease
Parkinson's disease is characterized by the selective loss of dopamine neurons, which leads to reduced control of voluntary locomotor activities. The cause of this degeneration is unknown; however...
-
Research Grant, 2014Validation of the Movement Disorders Society’s Clinical Criteria of Parkinson’s Disease
Study Rationale:
Diagnosis of Parkinson’s disease (PD) and other causes of parkinsonism is not always an easy task for physicians. An accurate diagnosis, however, is an essential aspect of care for... -
Rapid Response Innovation Awards, 2010Increasing Endogenous Neurogenesis Using Neurosteroids: A Novel Therapeutic Strategy to Treat Parkinson's Disease
Objective/Rationale:
We will test a locally produced brain chemical that increases the generation of new neurons to replace the damaged neurons in Parkinson disease (PD). The production of this... -
Biomarker Development, 2015Biomarker and DNA Samples Collection Add-on Study to the Phase III Trial of Isradipine
Study Rationale:
Isradipine, an FDA-approved agent for treatment of high blood pressure, was shown to be have neuroprotective benefit in models of Parkinson’s disease (PD). A recently completed Phase... -
Research Grant, 2016Therapeutic Effects of XPro1595 on Motor and Non-motor Outcomes in a Pre-clinical Model of Parkinson's disease
Study Rationale:
Studies funded under the 2012 TDI award revealed that peripheral administration of XPro1595 in the 6-OHDA (neurotoxin) pre-clinical model afforded significant neuroprotection against...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.